|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Enhancing Precision Oncology for Veterans through the VA's Strategic Partnerships
|
Isla Garraway, MD, Ph.D.
Isla Garraway discusses the innovative strides being made in the Veterans Affairs (VA) system toward improving cancer care for veterans, particularly African-American vets. She details the success of initiatives like the partnership with the Prostate Cancer Foundation and the Precision Oncology Program, which facilitate critical genetic testing for veterans with metastatic prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Unveiling the Clinical Potential of ctDNA: Implications for Prostate Cancer Management
|
Neeraj Agarwal, MD
Neeraj Agarwal delves into two ground-breaking studies, discussing the importance of ctDNA testing and the clinical implications of SPOP mutations in patients with metastatic prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Prostate Cancer and Veterans Health: A Spotlight on the Groundbreaking Initiatives in the VA System
|
Hiten Patel, MD, MPH
Hiten Patel discusses the important role of the Veterans Health Administration in prostate cancer treatment and research, emphasizing the creation of prostate cancer centers of excellence to enhance oncology care and survival rates for veterans.
|
|
|
|
|
|
|
|
|
|
|
| First Results of the PROMPT Trial: Precision Oncology Allocation in Patients with Early CRPC Following Routine Molecular Profiling
|
| Iris Kloots, MD
|
| Iris Kloots presents the first results of the PROMPT trial, which focuses on precision oncology allocation in patients with early castration-resistant prostate cancer (CRPC) following routine molecular profiling. This study explores the potential benefits of personalized treatment strategies based on molecular profiling to improve outcomes for patients with early CRPC.
|
|
|
|
|
|
| The Androgen Receptor Remains the Main Driver of Disease: Towards Third-Generation Inhibitors?
|
| Alice Bernard-Tessier, MD |
| Alice Bernard-Tessier discusses the significance of the androgen receptor as the main driver of prostate cancer and the emergence of third-generation inhibitors. The focus is on advancements in targeting the androgen receptor to develop more effective treatments for prostate cancer patients.
|
|
|
|
|
|
|
|
|
|
|
| Follow-Up Lecture: Somatic Testing — What’s the Difference? Why Bother?
|
| Peter Carroll, MD, MPH
|
| Peter Carroll provides a follow-up lecture on somatic testing in prostate cancer. Dr. Carroll explains the significance of somatic testing, which targets specific genetic mutations unique to tumor cells, allowing for personalized treatment approaches based on a better understanding of the tumor's biology and molecular drivers. |
|
|
|
|
|
| Using Biomarkers and Somatic Testing to Guide Treatment Choices
|
| Ana Aparicio, MD
|
| Ana Aparicio discusses the role of biomarkers and somatic testing to guide treatment choices in advanced prostate cancer. Dr. Aparicio notes that HRR, MSI, and PSMA uptake are predictive of benefits from specific treatment approaches. Ongoing improvements in assays for the detection of these markers are anticipated. However, the development of classifiers to guide therapeutic strategies remains a critically needed area of research.
|
|
|
|
|
|
|
